申请人:Hoffmann-La Roche Inc.
公开号:US04587256A1
公开(公告)日:1986-05-06
The invention relates to with novel thiazolidine derivatives of the formula ##STR1## wherein X is methylene, oxygen or sulfur; R.sup.1 is halogen; R.sup.2 is hydrogen, nitro, cyano, OR.sup.3 or NHR.sup.3 ; or R.sup.1 and R.sup.2 both simultaneously are hydrogen or nitro; R.sup.3 is hydrogen, alkyl, acyl, --CO--OR.sup.4 or --CO--NHR.sup.4 ; and R.sup.4 is alkyl, unsubstituted or substituted aryl or aralkyl, and their salts with physiologically compatible cations. The compounds of formula I are useful in the treatment of metabolic disorders.
本发明涉及一种新型噻唑烷衍生物,其化学式为## STR1 ##其中X为亚甲基,氧或硫;R.sup.1为卤素;R.sup.2为氢,硝基,氰基,OR.sup.3或NHR.sup.3;或R.sup.1和R.sup.2同时为氢或硝基;R.sup.3为氢,烷基,酰基,-CO-OR.sup.4或-CO-NHR.sup.4;R.sup.4为烷基,未取代或取代的芳基或芳基烷基,以及它们与生理兼容阳离子的盐。式I的化合物在治疗代谢紊乱方面是有用的。